TrialPloS one2024

A low molecular weight dextran sulphate, ILB®, for the treatment of amyotrophic lateral sclerosis (ALS): An open-label, single-arm, single-centre, phase II trial.

Venkataramanan Srinivasan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.